Exact Sciences reported a record third quarter, underscoring its growing impact on early cancer detection. The company announced it helped more than 1.4 million people better understand and manage their cancer risk — a milestone reflecting its mission to eradicate cancer through prevention, early detection, and personalized treatment.
Core revenue climbed 20% to $851 million, led by the continued success of Cologuard®, which reached record awareness levels this quarter with over 12,000 new providers ordering the test. Its oncology portfolio — including Oncotype DX® and the newly launched Cancerguard® multi-cancer early detection blood test — also saw strong global expansion.
With record cash flow, raised full-year guidance, and growing momentum across its screening and precision oncology businesses, Exact Sciences continues to solidify its position as a leader in cancer prevention and early detection.